Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$113.18 USD

113.18
24,053

-2.27 (-1.97%)

Updated Nov 15, 2024 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

LGND vs. ALKS: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. ALKS: Which Stock Is the Better Value Option?

Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

by Zacks Equity Research

Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

Ligand Pharmaceuticals (LGND) Q3 Earnings Miss Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -24.62% and 7.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand (LGND) Surges: Stock Moves 6.3% Higher

by Zacks Equity Research

Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retrophin Down on Neurological Disorder Drug Study Failure

by Zacks Equity Research

Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 11.48% and 9.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand Inks Oncology Drug Discovery Deal With PhoreMost

by Zacks Equity Research

Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

Ligand Grants Preclinical Candidate Rights to UK-based Firm

by Zacks Equity Research

Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

by Zacks Equity Research

AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

    Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

    by Zacks Equity Research

    Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

    Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

    Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1

    by Zacks Equity Research

    Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

    Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down

    by Zacks Equity Research

    Ligand (LGND) first-quarter earnings and sales decrease year over year.

    Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates

    by Zacks Equity Research

    Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

    Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

    by Zacks Equity Research

    Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

    Sanghamitra Saha headshot

    Rising P/E an Overlooked Criterion: 5 Top Stocks

    by Sanghamitra Saha

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.

    LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    LGND vs. ILMN: Which Stock Is the Better Value Option?

    Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals

    by Zacks Equity Research

    Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals

    4 High Earnings Yield Stocks to Strengthen Your Portfolio

    by Zacks Equity Research

    Earnings yield is very effective for finding out undervalued stocks.